Document Detail

VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer.
MedLine Citation:
PMID:  8204348     Owner:  NLM     Status:  MEDLINE    
Thirty-seven extensive disease SCLC patients were treated with ifosfamide 1.0 g/m2 (maximum 1.75 g), VP-16 (etoposide) 75 mg/m2 and cisplatin 20 mg/m2 (VIP) daily for 5 days in hospital. Mesna was given as a continuous infusion until 12 h after the last ifosfamide dose. Treatment was reduced to 4 days after the first 8 patients experienced serious myelotoxicity. 30 patients were evaluable for response. 8 (27%) achieved a complete response and 60% had a partial response. The median duration of response was 23 weeks. The median survival of all 37 patients was 41 weeks, and 47 weeks for the 30 evaluable patients. Fifty per cent and 26% of the evaluable treatment courses were associated with grade 4 and 3 granulocytopenia, respectively. There were eight febrile events including four treatment-related deaths from sepsis on the 5-day regimen. Although the response to VIP was generally rapid, the proportion achieving complete response (27% of evaluable patients) and the median survival is similar to standard chemotherapy regimens which are less toxic and less complex to administer.
W K Evans; D J Stewart; F A Shepherd; D Logan; G Goss; J A Maroun; R Wierzbicki; E Warner; J Latreille; S Dahrouge
Related Documents :
11589488 - Three conventional-drug combination (ifosfamide, carboplatin, etoposide--ice regimen) i...
17923188 - Continuous remission in an infant with chest wall malignant rhabdoid tumor after relapse.
10597208 - High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient ...
9876058 - Ifosfamide and actinomycin-d, added in the induction phase to vincristine, cyclophospha...
7630168 - Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predi...
25147768 - Osteitis pubis: can early return to elite competition be contemplated?
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  30A     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  1994  
Date Detail:
Created Date:  1994-07-13     Completed Date:  1994-07-13     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  299-303     Citation Subset:  IM    
Ottawa Regional Cancer Centre, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Agranulocytosis / chemically induced
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Small Cell / drug therapy*
Cisplatin / administration & dosage,  adverse effects
Etoposide / administration & dosage,  adverse effects
Ifosfamide / administration & dosage,  adverse effects
Lung Neoplasms / drug therapy*
Middle Aged
Treatment Outcome
Reg. No./Substance:
0/ICE protocol 1; 15663-27-1/Cisplatin; 33419-42-0/Etoposide; 3778-73-2/Ifosfamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inconsistent expression of HLA-B antigens on peripheral blood lymphocytes of stage I melanoma patien...
Next Document:  Subsequent primary cancers following bladder cancer.